4//SEC Filing
Egholm Michael 4
Accession 0000950170-24-042373
CIK 0001162194other
Filed
Apr 4, 8:00 PM ET
Accepted
Apr 5, 6:59 PM ET
Size
10.9 KB
Accession
0000950170-24-042373
Insider Transaction Report
Form 4
Egholm Michael
DirectorPresident & CEO
Transactions
- Exercise/Conversion
Common Stock
2024-04-04+196,512→ 422,030 total - Award
Common Stock
2024-04-05+212,126→ 634,156 total - Exercise/Conversion
Restricted Stock Units
2024-04-04−196,512→ 393,025 total→ Common Stock (196,512 underlying) - Award
Common Stock
2024-01-05+9,006→ 225,518 total
Footnotes (4)
- [F1]Received in exchange for 8,114 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger, dated October 4, 2023, by and among Standard BioTools Inc. (the "Issuer"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Issuer's common stock at the effective time of the Merger.
- [F2]On April 11, 2023, the Reporting Person was granted a target amount of 231,579 performance-based restricted stock units ("RSUs") under the Issuer's 2011 Equity Incentive Plan, as amended. Each RSU represent the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions. On April 5, 2024, the Board of Directors of the Issuer determined that certain of the RSU performance-based conditions were met resulting in the vesting of 212,126 RSUs as of March 31, 2024.
- [F3]Each RSU represents the contingent right to receive one share of the Issuer's common stock.
- [F4]On April 4, 2022, the Reporting Person was granted 786,049 RSUs, vesting in four equal annual installments beginning on April 4, 2023.
Documents
Issuer
STANDARD BIOTOOLS INC.
CIK 0001162194
Entity typeother
Related Parties
1- filerCIK 0001559779
Filing Metadata
- Form type
- 4
- Filed
- Apr 4, 8:00 PM ET
- Accepted
- Apr 5, 6:59 PM ET
- Size
- 10.9 KB